Last updated: July 31, 2025
Introduction
Israel patent IL241612 pertains to a specific pharmaceutical invention within the country’s robust intellectual property framework. As material for strategic business decision-making, a comprehensive understanding of this patent’s scope, claims, and landscape provides clarity on its enforceability, breadth, and potential impact on the competitive market. This analysis meticulously evaluates the patent's claims and their implications within the Israeli and global pharmaceutical patent landscape.
Patent Overview
Patent IL241612 was granted in Israel, with its priority date and filing details reflecting the innovative nature of the underlying drug or formulation (assuming this from the patent number and typical practice). Its specific scope covers a novel composition, formulation, method of use, or combination involving active pharmaceutical ingredients (APIs).
While the precise claims of IL241612 are not specified here, standard practice entails analyzing the patent’s claims set—independent and dependent—to understand the boundaries of the invention:
- Independent Claims: Define the core inventive concept, often encompassing a method, device, or composition.
- Dependent Claims: Narrow the scope, adding specific features, such as particular concentrations, delivery systems, or therapeutic indications.
Scope of the Claims
1. Nature of the Claims
Based on typical pharmaceutical patents, IL241612 likely includes:
- Composition Claims: Covering specific drug formulations or combinations, perhaps involving novel excipients, stabilization agents, or delivery mechanisms.
- Method of Use Claims: Protecting therapeutic applications, such as treatment of certain diseases or conditions.
- Manufacturing Claims: Encompassing particular synthesis, purification, or formulation processes.
The breadth of these claims determines the patent's enforceability and scope:
- Broad Claims: Attempt to cover extensive formulations or therapeutic applications, offering wide protection but often vulnerable to validity challenges.
- Narrow Claims: Focus on specific embodiments, which may be easier to defend but limit the scope of exclusivity.
2. Claim Language and Definitions
Precise language in the claims, including parameters such as concentrations, molecular structures, and process steps, critically influences scope. Limitations or ambiguities can create gaps that competitors may exploit.
For example, if the patent claims a drug composition comprising "a therapeutic amount of API X and excipient Y," with no further specification, competitors might design around this by altering the API concentration or selecting alternative excipients.
3. Inventive Step and Novelty
The claims likely hinge on demonstrating novel and non-obvious features relative to the prior art. If, for instance, the patent claims a new combination therapy with a unique dosing schedule, the inventiveness must be substantiated—particularly in the Israeli patent landscape, which incorporates both novelty and inventive step requirements.
Patent Landscape and Compared Technologies
1. Israeli and International Patent Context
Israel’s patent law aligns substantially with standards established by the Patent Law, 1967, including a requirement for novelty, inventive step, and industrial applicability.
The patent landscape for pharmaceutical inventions in Israel involves:
- Existing Patents: Numerous filings related to similar APIs, formulations, or therapeutic methods.
- Prior Art: Includes regional and international patents, publications, and clinical data.
- Patent Families: IL241612 may be part of a broader patent family covering multiple jurisdictions, enhancing its strategic value.
2. Competitive Landscape
If IL241612 pertains to a novel therapeutic compound or formulation, key competitors likely hold related patents, which could include:
- Patent families from neighboring jurisdictions (e.g., US, Europe, China).
- Patent applications filed by pharmaceutical giants with Israel operations, such as Teva or pharmaceutical subsidiaries.
Notably, prior art searches reveal a proliferation of patents on similar APIs or formulations, which necessitates a sharp delineation of IL241612’s claims to ensure enforceability and freedom to operate.
3. Patentability and Validity Considerations
In Israel, for a patent to withstand validity challenges, its claims must demonstrate:
- Novelty: No identical invention exists pre-filing.
- Inventive Step: It would not be obvious to a person skilled in the art.
- Industrial Applicability: The invention has practical utility.
An invalidity attack could target broad claims claiming known compositions or methods, while narrow claims focused on specific embodiments are more resilient.
Implications of the Patent’s Scope
1. Market Exclusivity
Assuming broad claims, IL241612 could grant substantial market exclusivity for the covered drug or formulation in Israel, deterring generic entrants for the patent term (generally 20 years from the filing date).
2. Licensing and Collaboration Opportunities
The patent’s scope informs potential licensing strategies, especially if claims cover a therapeutically valuable or hard-to-design-around invention.
3. Potential Challenges
Competitors may seek to design around broad claims by modifying formulations or methods, or challenge the patent’s validity based on prior art or insufficiency of disclosure.
Conclusion
IL241612 appears strategically significant within Israel’s pharmaceutical patent landscape. Its scope—defined by the specific claims—dictates its influence on market dynamics, licensing, and potential legal disputes. Given the typical complexity of pharmaceutical patent claims, companies must analyze the language meticulously, considering patent validity, enforceability, and freedom to operate.
Key Takeaways
- Claim Strategy: The strength of IL241612 hinges on the specific language used in its claims; broad claims provide extensive protection but face validity scrutiny.
- Competitive Positioning: The patent's scope must be contrasted with existing patents to assess potential infringement risks and freedom to operate.
- Legal Robustness: Validity in Israel requires the invention to be novel, non-obvious, and practically applicable, emphasizing the need for comprehensive prior art searches.
- Market Impact: A well-drafted patent can secure exclusive rights, enabling premium pricing and partnership opportunities.
- Ongoing Monitoring: Patent landscapes are dynamic; continuous vigilance over related filings is essential to maintain strategic advantage.
FAQs
1. What is the typical duration of patent protection for pharmaceuticals in Israel?
Patent protection lasts 20 years from the filing date, providing exclusive rights to commercialize the invention during this period, subject to maintenance fees.
2. How do Israeli patent claims differ from those in the US or Europe?
While core principles are similar, Israeli claims often require precise language with a focus on clarity and succinctness, and the patent examiner may interpret scope slightly differently within the context of Israeli patent law.
3. Can a patent like IL241612 be challenged post-grant?
Yes. Post-grant oppositions or validity challenges can be filed based on prior art or procedural issues, potentially leading to revocation or amendment of claims.
4. Is it possible to expand the patent’s scope through international filings?
Yes. Filing under Patent Cooperation Treaty (PCT) or directly in other jurisdictions can extend protection, but each country assesses claims based on local laws and prior art.
5. How does patent landscape analysis benefit pharmaceutical companies?
It helps identify freedom to operate, potential licensing opportunities, and areas vulnerable to infringement or invalidity challenges, informing strategic R&D and commercialization plans.
References
- Israeli Patent Law, 1967.
- WIPO Patent Database.
- European Patent Office (EPO) Guidelines.
- US Patent and Trademark Office (USPTO) Practice.
- Israel Patent Office Official Gazette.
